Literature DB >> 2061446

Chemotherapy-induced acral erythema.

B R Baack1, W H Burgdorf.   

Abstract

Chemotherapy-induced acral erythema has been described in association with several different chemotherapy regimens. We review the literature on this topic and suggest that different mechanisms may be responsible for the clinically heterogeneous array of acral changes.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2061446     DOI： 10.1016/0190-9622(91)70073-b

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  22 in total

Review 1.  [Skin changes with chemotherapy].

Authors:  A L Branzan; M Landthaler; R-M Szeimies
Journal:  Hautarzt       Date:  2005-06       Impact factor: 0.751

2.  Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.

Authors:  Rena C Zuo; Andrea B Apolo; John J DiGiovanna; Howard L Parnes; Corrine M Keen; Swati Nanda; William L Dahut; Edward W Cowen
Journal:  JAMA Dermatol       Date:  2015-02       Impact factor: 10.282

3.  [Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer].

Authors:  C Sauter; A Saborowski; H-M Ockenfels
Journal:  Hautarzt       Date:  2007-07       Impact factor: 0.751

4.  Etoposide-related acral erythema.

Authors:  I Portal; F Cardenal; X Garcia-del-Muro
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome.

Authors:  Vincent Sibaud; Florence Dalenc; Christine Chevreau; Henri Roché; Jean-Pierre Delord; Loïc Mourey; Jean-Louis Lacaze; Nora Rahhali; Charles Taïeb
Journal:  Oncologist       Date:  2011-09-30

6.  The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.

Authors:  Rong-Xin Zhang; Xiao-Jun Wu; Shi-Xun Lu; Zhi-Zhong Pan; De-Sen Wan; Gong Chen
Journal:  J Cancer Res Clin Oncol       Date:  2010-11-27       Impact factor: 4.553

7.  Cutaneous toxicity of oral low-dose methotrexate.

Authors:  Priyanka Jalandhara; Gurjit Kaeley
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-05-22

8.  Hand-foot syndrome due to capecitabine.

Authors:  Amar Surjushe; Resham Vasani; Sudhir Medhekar; Minal Thakre; D G Saple
Journal:  Indian J Dermatol       Date:  2008-01       Impact factor: 1.494

9.  Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.

Authors:  Hyun-Sook Son; Woo Yong Lee; Won-Suk Lee; Seong Hyeon Yun; Ho-Kyung Chun
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

10.  Hand-foot syndrome due to capecitabine.

Authors:  Amar Surjushe; Resham Vasani; Sudhir Medhekar; Minal Thakre; D G Saple
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.